NOVO — Marts 2024
-
Nivån på riktkurserna visar stor spridning från Kepler Cheuvreux med en riktkurs på 715 danska kronor upp till Deutsche Banks riktkurs som har tagits upp till 1.100 danska kronor från tidigare 950 kronor.
-
På torsdagen steg Novo Nordisk aktie med över 8 procent. I den tidiga handeln på fredagen har aktien backat med 1 procent till 910:70 danska kronor.
-
ANALYSHUS REKOMMENDATION RIKTKURS I DKK
Barclays Övervikt 1.050 (900)
Citi Köp 975
Deutsche Bank Köp 1.100 (950)
Jefferies Underperform i.u.
Kepler Cheuvreux Behåll 715
Nordea Köp 1.045 (885)
Ålandsbanken - 1.000
Magnus Bernet +46 8 5191 7953 Nyhetsbyrån Direkt
-
Ser ud til hovedparten af analytikerne har øget target med 100-150
-
Novo Nordisk får endnu et løftet kursmål: DNB spår 1100 kr. https://www.proinvestor.com/investornyt/1128969/novo-nordisk-far-endnu-et-loftet-kursmal-dnb-spar-1100-kr
-
NyKredit hæver fra 900 til 1050
-
Se evt i debatten for ny info om Amycretin
-
Av LLY får ny forsinkelse fra FDA på deres Alzheimers stof. https://www.proinvestor.com/investornyt/1129011/eli-lillys-alzheimerskandidat-star-over-for-yderligere-forsinkelse
-
Novos topchef om risiko for kopikonkurrence: Produktionen giver os en konkurrencefordel https://www.proinvestor.com/investornyt/1129075/novos-topchef-om-risiko-for-kopikonkurrence-produktionen-giver-os-en-konkurrencefordel
-
Novos milliardkøb af fyldefabrikker undersøgt nøje - forventer ikke juridiske bespænd https://www.proinvestor.com/investornyt/1129180/novos-milliardkob-af-fyldefabrikker-undersogt-noje-forventer-ikke-juridiske-bespaend
-
Wegovy
approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease https://www.proinvestor.com/boards/119263 -
Novo Nordisk CEO says experimental weight loss pill could become a best-in-class drug https://www.cnbc.com/2024/03/08/novo-nordisk-ceo-weight-loss-pill-could-become-a-best-in-class-drug.html
-
Jeg tror, at dette er det orale fase 1 amycretin forsøg på clinical trials. https://clinicaltrials.gov/study/NCT06049329?term=amycretin&rank=1&tab=table
-
Det primære endemål i fase 1 forsøget med Amycretin var “Number of treatment emergent adverse events (TEAE)”. https://clinicaltrials.gov/study/NCT06049329?intr=Amycretin&rank=1
-
De sekundære endemål var: AUC,MD; the area under the NNC0487-0111 plasma concentration-time curve after last multile dose, Cmax,MD; the maximum plasma concentration of NNC0487-0111 after last multiple dose, tmax,MD; the time of maximum plasma concentration of NNC0487-0111 after last multiple dose.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind